KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Goodwill: 2020-2024

Historic Goodwill for Supernus Pharmaceuticals (SUPN) over the last 5 years, with Dec 2024 value amounting to $117.0 million.

  • Supernus Pharmaceuticals' Goodwill rose 1.76% to $119.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.1 million, marking a year-over-year increase of 1.76%. This contributed to the annual value of $117.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • Supernus Pharmaceuticals' Goodwill amounted to $117.0 million in FY2024, which was down 0.00% from $117.0 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Goodwill ranged from a high of $117.5 million in FY2021 and a low of $77.9 million during FY2020.
  • Its 3-year average for Goodwill is $117.0 million, with a median of $117.0 million in 2024.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Goodwill soared by 50.83% in 2021, and later fell by 0.42% in 2022.
  • Supernus Pharmaceuticals' Goodwill (Yearly) stood at $77.9 million in 2020, then soared by 50.83% to $117.5 million in 2021, then fell by 0.42% to $117.0 million in 2022, then remained steady at $117.0 million in 2023, then remained steady at $117.0 million in 2024.